Oculus Innovative Sciences, Inc. develops, manufactures and markets a family of tissue care products to treat infections and, through a separate mechanism of action, enhance healing while reducing the need for antibiotics. The Company�s platform technology, called Microcyn, is a solution of electrically charged oxychlorine small molecules designed to treat a range of organisms that cause disease (pathogens). Microcyn has received seven 510(k) clearances for use as a medical device in wound care management (cleaning, debridement, lubricating, moistening and dressing) including for acute and chronic wounds, as well as in dermatology applications. As of March 31, 2011, the Company was making Microcyn Technology-based human wound care products available, both as prescription and over-the-counter products, under its seven 510(k) clearances in the United States. In laboratory tests, Microcyn has been shown to destroy certain biofilms.